These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16947044)

  • 1. Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients.
    Sueoka N; Sato A; Eguchi H; Komiya K; Sakuragi T; Mitsuoka M; Satoh T; Hayashi S; Nakachi K; Sueoka E
    J Cancer Res Clin Oncol; 2007 Feb; 133(2):93-102. PubMed ID: 16947044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer.
    Cohen V; Agulnik JS; Jarry J; Batist G; Small D; Kreisman H; Tejada NA; Miller WH; Chong G
    Cancer; 2006 Dec; 107(12):2858-65. PubMed ID: 17096434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer tumor specimens from various ways by denaturing high-performance liquid chromatography].
    Chen S; Chen Z; Guo A; Su J; Huang Y; Chen S; Zhang X; Yang X; Yang J; Wu Y
    Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):850-5. PubMed ID: 20840812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.
    Jänne PA; Borras AM; Kuang Y; Rogers AM; Joshi VA; Liyanage H; Lindeman N; Lee JC; Halmos B; Maher EA; Distel RJ; Meyerson M; Johnson BE
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):751-8. PubMed ID: 16467085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three methods for detecting epidermal growth factor receptor mutations in plasma DNA samples of Chinese patients with advanced non-small cell lung cancer.
    Qin L; Zhong W; Zhang L; Li LY; Wang MZ
    Chin Med J (Engl); 2011 Mar; 124(6):887-91. PubMed ID: 21518597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The detection by denaturing high performance liquid chromatography of epidermal growth factor receptor mutation in tissue and peripheral blood from patients with advanced non-small cell lung cancer].
    Bai H; Zhao J; Wang SH; An TT; Wang X; Wu MN; Duan JC; Yang L; Guo QZ; Liu NH; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Dec; 31(12):891-6. PubMed ID: 19134404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct sequencing in cytological specimens as a useful strategy for detecting EGFR mutations in non-small cell lung cancer patients.
    Cho MC; Choi CM; Kim S; Jang S; Jang S; Park CJ; Chi HS; Peyton MJ; Lee W; Chun S; Kim SW; Min WK
    Clin Chem Lab Med; 2011 Sep; 50(3):565-72. PubMed ID: 21899495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Chu H; Zhong C; Xue G; Liang X; Wang J; Liu Y; Zhao S; Zhou Q; Bi J
    Oncol Rep; 2013 Nov; 30(5):2311-5. PubMed ID: 24002698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors.
    Sihto H; Puputti M; Pulli L; Tynninen O; Koskinen W; Aaltonen LM; Tanner M; Böhling T; Visakorpi T; Bützow R; Knuuttila A; Nupponen NN; Joensuu H
    J Mol Med (Berl); 2005 Dec; 83(12):976-83. PubMed ID: 16133419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
    Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
    Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
    Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
    Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.
    Pan Q; Pao W; Ladanyi M
    J Mol Diagn; 2005 Aug; 7(3):396-403. PubMed ID: 16049312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR and erbB2 mutation status in Japanese lung cancer patients.
    Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
    Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
    Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N
    Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
    Pao W; Miller V; Zakowski M; Doherty J; Politi K; Sarkaria I; Singh B; Heelan R; Rusch V; Fulton L; Mardis E; Kupfer D; Wilson R; Kris M; Varmus H
    Proc Natl Acad Sci U S A; 2004 Sep; 101(36):13306-11. PubMed ID: 15329413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.